CoChat

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men.

Veldhuis, J. D., Bidlingmaier, M., Anderson, S. M., Evans, W. S., Wu, Z., Strasburger, C. J. · 2002 · The Journal of Clinical Endocrinology & Metabolism

Abstract

Organs that respond to and metabolize GH are enriched in cognate high-affinity receptors. However, whether isologous receptors mediate the de facto access of ligand to cellular degradative pathways is not known. To address this query, we assessed the distribution and whole-body elimination kinetics of (endogenous and exogenous) GH before and after administration of a novel, potent, and selective recombinant human (rh) GH receptor antagonist peptide, pegvisomant. Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study. The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively. The half-life, metabolic clearance rate (MCR), and distribution volume of GH were quantitated by way of: 1) deconvolution analysis of serum GH concentration time series collected every 10 min for 10 h; 2) exponential regression analysis of the decay of GH concentrations after a 6-min iv pulse of rhGH (1 and 10 μg/kg); 3) calculation of the MCR during constant iv infusion of rhGH (0.5 and 5.0 μg/kg every 2 h); and 4) exponential fitting of the elimination time-course of GH concentrations following cessation of each constant infusion. Concentrations of GH and pegvisomant were measured in separate, noncross-reactive, two-site monoclonal, immunofluorometric assays. Pegvisomant concentrations averaged 4860 ± 480 μg/liter (±sem) across the infusion interval, thus exceeding low steady state GH concentrations by 3000-fold. Inhibitory efficacy of the GH receptor antagonist peptide was affirmed by way of a 34% reduction in the serum total IGF-I concentration, i.e., from 257 ± 37 (placebo) to 170 ± 24 (drug) μg/liter (P < 0.001); and a reciprocal 77% elevation of the (10-h) mean GH concentration, i.e., from 1.3 ± 0.23 (placebo) to 2.3 ± 0.42 (drug) μg/liter (P = 0.003). ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 ± 1.3 (placebo) and 14 ± 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 ± 1.0 (placebo) and 13 ± 0.5 (drug) (for the 10 μg/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 ± 6.2 (placebo) and 58 ± 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 μg/kg every 2 h), 18.2 ± 2.4 (placebo) and 18.3 ± 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 ± 0.98 (placebo) and 16 ± 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 ± 0.32 (placebo) and 3.5 ± 0.31 (drug). In ensemble, the present data refute the a priori postulate that vascular-accessible GH receptors determine the in vivo pseudoequilibrium kinetics of GH disappearance in the human.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2001-011885

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 1

  1. Guyton, 2000, The body fluid compartments: extracellular and intracellular fluids; interstitial fluid and edema, In: Textbook of medical physiology, vol 10. Philadelphia: WB Saunders Co.;, 264

Cited by

See all 64

Metadata

Authors
Veldhuis, J. D., Bidlingmaier, M., Anderson, S. M., Evans, W. S., Wu, Z., & Strasburger, C. J.
Affiliations
  • University of Virginia Health System (US)
  • LMU Klinikum (DE)
Corresponding author
Veldhuis, J. D.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2002-12-01
Volume
87
Issue
12
Pages
5737-5745
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2066506983
Cited by
61
References
45
Citations by year
2020: 3 · 2017: 4 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 1
FWCI
3.23
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Virginia
  • Deutsches Krebsforschungszentrum
  • National Institutes of Health (RR-00847)
  • National Institute on Aging (R01-AG14799-05, AG-19695-01, R01AG014799)
  • National Center for Research Resources (M01RR000847, MO1-RR00847)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
growth hormone, growth hormone receptor, pegvisomant, growth hormone receptor antagonist, metabolic clearance rate, volume of distribution, elimination half-life, insulin-like growth factor I, recombinant human growth hormone, healthy adults, sex differences, deconvolution, growth hormone binding protein
MeSH terms
Adult, Double-Blind Method, Female, Humans, Kinetics, Male, Prospective Studies, Receptors, Somatotropin, Recombinant Proteins, Reference Values, Cross-Over Studies, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. https://app.cochat.ai/papers/10.1210/jc.2001-011885
The paper
Veldhuis, J. D., Bidlingmaier, M., Anderson, S. M., Evans, W. S., Wu, Z., & Strasburger, C. J. (2002). Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2001-011885

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.